Subclassification of ovarian cancer based on pathology and genetics

European Journal of Cancer

Volumn 45, Issue SUPPL. 1, 2009, Pages 427-428

  Prat, Jaime ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; BETA CATENIN; K RAS PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE;

ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GENETICS; CANCER GROWTH; CANCER MODEL; CANCER SCREENING; CARCINOGENESIS; CELL CYCLE REGULATION; CELL PROLIFERATION; CLEAR CELL CARCINOMA; CYSTADENOCARCINOMA; DISEASE CLASSIFICATION; DNA FINGERPRINTING; ENDOMETRIUM CARCINOMA; EPIGENETICS; GENE EXPRESSION; GENE MUTATION; GENE SILENCING; GENETIC RISK; HISTOPATHOLOGY; HUMAN; KARYOTYPE; MICROSCOPY; MOLECULAR GENETICS; MUCINOUS CARCINOMA; ONCOGENE; ONCOGENE K RAS; OUTCOME ASSESSMENT; OVARY CANCER; PRIORITY JOURNAL; RISK FACTOR; SEROSA; WORLD HEALTH ORGANIZATION;

FEMALE; HUMANS; MUTATION; OVARIAN NEOPLASMS;

EID: 70349114187     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(09)70076-0     Document Type: Article

References (12)

1. Prat J. Pathology of the Ovary (2004), Saunders, Philadelphia
2. Scully R.E., Young R.H., and Clement P.B. Tumors of the ovary, maldeveloped gonads, fallopian tube, and broad ligament. Atlas of Tumor Pathology. Third Series. Fascicle 23 (1998), Armed Forces Institute of Pathology, Washington D.C.
3. Leitao M.M., Boyd J., Hummer A., et al. Clinicopathological analysis of early-stage sporadic ovarian carcinoma. Am J Surg Pathol 28 (2004) 147-159
4. Singer G., Kurman R.J., Chang H.-W., Cho S.K.R., and Shih I.-M. Diverse tumorigenic pathways in ovarian serous carcinoma. Am J Pathol 160 (2002) 1223-1228
5. Bonome T., Lee J.Y., Park D.C., et al. Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res 65 (2005) 10602-10612
6. Cuatrecasas M., Villanueva A., Matias-Guiu X., and Prat J. K-ras mutations in mucinous ovarian tumors: a clinicopathologic and molecular study of 95 cases. Cancer 79 (1997) 1581-1586
7. Obata K., Morland S.J., Watson R.H., et al. Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors. Cancer Res 58 (1998) 2095-2097
8. Catasús L., Bussaglia E., Rodríguez I.M., et al. Molecular genetic alterations in endometrioid carcinomas of the ovary: Similar frequency of beta-catenin abnormalities but lower rate of microsatellite instability and PTEN alterations than in uterine endometrioid carcinomas. Hum Pathol 35 (2004) 1360-1368
9. Lee K.R., Tavassoli F.A., Prat J., et al. Tumours of the ovary and peritoneum: Surface epithelial-stromal tumours. In: Tavassoli F.A., and Devilee P. (Eds). World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs (2003), IARC Press, Lyon, France 117-124
10. Irving J.A., Catasus L., Gallardo A., et al. Synchronous endometrioid carcinomas of the uterine corpus and ovary: Alterations in the beta-catenin (CTNNB1) pathway are associated with independent primary tumors and favorable prognosis. Hum Pathol 36 (2005) 605-619
11. Press J.Z., de Luca A., Boyd N., et al. Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer 8 (2008) 17
12. Köbel M., Kalloger S.E., Carrick J., et al. A limited panel of immunomarkers can reliably distinguish between clear cell and high-grade serous carcinoma of the ovary. Am J Surg Pathol 33 (2009) 14